Prescription Drug Abuse and Workplace Absenteeism: Evidence from the 2008 2012 National Survey o n Drug Use and Health by Bray, Jeremy W. et al.
Prescription Drug Abuse and Workplace Absenteeism: Evidence from the 2008–2012 
National Survey on Drug Use and Health 
 
By: Martijn Van Hasselt, Vincent Keyes, Jeremy Bray, & Ted Miller 
 
Van Hasselt, M., Keyes, V., Bray, J., & Miller, T. (2015). Prescription drug abuse and workplace 
absenteeism: Evidence from the 2008-2012 National Survey on Drug Use and Health. Journal of 
Workplace Behavioral Health, 30, 379-392. DOI: 10.1080/15555240.2015.1047499. 
 
This is an Accepted Manuscript of an article published by Taylor & Francis in Journal of 
Workplace Behavioral Health on November 17, 2015, available online: 
http://www.tandfonline.com/10.1080/15555240.2015.1047499. 
 
Abstract:  
 
Prescription drug abuse has become increasingly prevalent in recent years, yet little is known 
about its impact on workplaces. This study investigated the relation between self-reported misuse 
of prescription pain relievers and other drugs and self-reported workplace absenteeism. Using 
data from the 2008–2012 National Survey on Drug Use and Health and controlling for 
confounding factors, the authors found that workers who reported misuse of prescription drugs 
were about 7% points more likely to report any past-month absenteeism. In addition, they were 
absent for an additional 0.25 days, compared to workers who did not report prescription drug 
misuse. The authors did not find evidence that these results varied for prescription pain relievers 
as compared to other prescription drugs. Future work is needed to study a broader range of 
workplace outcomes. 
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Article:  
 
Introduction 
 
Prescription drug abuse has become increasingly prevalent in recent years. Data from the 
National Survey on Drug Use and Health (NSDUH) show that in 2011 an estimated 6.1 million 
people age 12 and older used prescription drugs nonmedically during the prior month (Substance 
Abuse and Mental Health Services Administration [SAMHSA], 2012a). The majority of 
nonmedical users (4.5 million) used prescription pain relievers. Perhaps more troubling is that in 
2010 an estimated 2.4 million people used prescription drugs nonmedically “for the first time” 
during the past year. New users tend to be young, with an average age of 22 years. Individuals 
age 12 to 25 years old were more likely to misuse prescription drugs than any other type of illicit 
drug except marijuana (SAMHSA, 2012a). 
 
The prevalence of prescription drug misuse has had a significant impact on health and health 
care utilization. Between 1999 and 2010 the death rate due to the abuse of prescription opioid 
pain relievers—the type of prescription drug that is most commonly misused—increased 
fourfold (Jones, Mack, & Paulozzi, 2013; Paulozzi, Jones, Mack, & Rudd, 2011). In 2010 an 
estimated 38,329 deaths were associated with drug overdoses. In 58% of those deaths one or 
more prescription drugs were involved. Between 2004 and 2010 the estimated number of 
emergency room (ER) visits that involved the nonmedical use of pharmaceuticals rose from 
626,472 to 1,345,645 visits (SAMHSA, 2012b). Among individuals age 12 and older admitted to 
substance abuse treatment facilities, the percentage who reported abusing prescription pain 
relievers rose from 2.2% in 1998 to 9.8% in 2008; the corresponding rise for benzodiazepine 
abuse was from 1.3 to 3.2% (SAMHSA, 2010). 
 
Recently, several studies have calculated societal cost estimates for the most frequently misused 
category of prescription drugs, namely, opioid pain relievers such as OxyContin and Vicodin. 
The estimates are quite variable. Total economic cost of prescription opioid abuse was estimated 
at $8.6 billion in 2001, $4.6 billion (53%) of which was attributed to the workplace in terms of 
wage losses due to reduced productivity, premature death, incarceration, and reduced 
employment (Birnbaum et al., 2006). Total economic costs in 2006 and 2007 were estimated at 
$53.4 billion and $55.7 billion, respectively (Birnbaum et al., 2011; Hansen, Oster, Edelsberg, 
Woody, & Sullivan, 2011). The share of costs that was attributed to lost productivity in these 
years was 79% and 46%. In 2009, medical and productivity costs of opioid poisoning—a 
category that captures portions of misuse and misadventure in high-dose therapeutic use—were 
estimated at $20.4 billion, including absenteeism costs of $335 million and forgone future 
earnings due to mortality of $18.2 billion (Inocencio, Carroll, Read, & Holdford, 2013). The 
large range of cost estimates results from differences in the methodology and data sources used. 
 
The current evidence points to a nontrivial prevalence of prescription drug misuse in the 
workplace and suggests that the costs to workplaces could be substantial (Birnbaum et al., 2011; 
Reutsch, 2010). These costs arise for a number of reasons. First, employees who misuse 
prescription drugs may be less likely to show up for work (absenteeism) and may be less 
productive when they are at work (Serxner, Gold, & Bultman, 2001). For example, a study using 
data from the 2002–2004 NSDUH showed that nonmedical users of prescription opioids were 
significantly more likely to experience psychiatric symptoms of panic, depression, and social 
phobia/agoraphobia, conditions that are likely to affect job performance (Becker, Sullivan, 
Tetrault, Desai, & Fiellin, 2008). Second, substance use is associated with workplace injuries, 
which can be extremely costly to employers (Ramchand, Pomeroy, & Arkes, 2009). Third, 
prescription drug misuse may lead to increased job turnover. Fourth, the cost to employers of 
employee medical insurance can rise due to higher health care utilization among those workers 
who misuse prescription drugs. 
 
In this study, we focus on one outcome in particular, namely absenteeism, and empirically 
quantify its relation with (self-reported) prescription drug misuse among workers. Employees 
who misuse prescription drugs are more likely to be impaired and may therefore be more likely 
to avoid work or to take advantage of paid time off. The focus on absenteeism alone is partly 
determined by data limitations in this study sample. An assessment of the relation between other 
workplace variables and prescription drug misuse is therefore left for future study. However, 
absenteeism is an important variable to study, because it is arguably a more immediate result of 
prescription drug misuse and can subsequently affect the workplace and employers in several, 
negative ways. First, it directly reduces productivity and profitability. One study estimated the 
average annual cost to employers of unscheduled absenteeism as high as $660 per employee 
(Navarro & Bass, 2006). Second, repeated absenteeism can also erode relations and increase 
tension among employees particularly if it is suspected that the absenteeism is related to drug 
abuse. 
 
To our knowledge, only two studies explicitly considered absenteeism and associated costs in 
relation to prescription opioid misuse. One study estimated the total cost of excess disability and 
medically related absenteeism due to prescription opioid abuse at $2.6 billion in 2007, or 10.2% 
of total productivity losses (Birnbaum et al., 2011). The second study considered only opioid 
poisoning and estimated the costs of absenteeism at $335 million in 2009, or 1.8% of total 
productivity losses (Inocencio et al., 2013). This study is different and novel in several respects. 
First, the two previous studies estimated absenteeism due to health care utilization on the basis of 
claims and utilization data. In this context, a day spent in the ER or hospital was a lost day of 
work. In contrast, this study uses a self-reported measure of absenteeism, where absenteeism can 
be related to sickness, injury, or a lack of motivation. Second, there is a difference in how the 
population of workers who misuse prescription drugs is identified. The previous studies used a 
clinical diagnosis of opioid misuse and abuse (Birnbaum et al., 2011) or a clinical diagnosis of 
opioid poisoning (Inocencio et al., 2013). In contrast, this study relies on self-reported misuse, 
and we investigate not only misuse of prescription opioids but also misuse of other prescription 
drugs. Third, our analysis is based on data from the NSDUH from a more recent time period. The 
use of recent data is important, given the surge in prescription drug misuse in recent years. The 
advantage of using the NSDUH is that it provides a nationally representative sample. Moreover, 
the NSDUH contains a rich set of individual and workplace characteristics, which allows us to 
analyze the relation between prescription drug misuse and absenteeism in a regression 
framework, while (partially) controlling for other, confounding factors that affect absenteeism. 
Although to some extent the previous studies controlled for basic demographic characteristics, 
we used additional controls for physical and mental health, the use of other substances, 
workplace characteristics and occupation type. 
 
Method 
 
Data and Sample Selection 
 
We used data from the 2008–2012 NSDUH. The NSDUH is a nationally representative survey of 
the noninstitutionalized population in the United States age 12 or older (SAMHSA, 2012a). The 
survey contains a prescription drug module that was specifically designed to measure misuse. 
The sample for this analysis was restricted to those who were age 18 or older at the time of the 
interview and who reported having current part-time or full-time employment. Of the 191,132 
respondents who were age 18 years or older, a total of 122,346 respondents (64%) reported 
current part-time or full-time employment. 
 
Absenteeism and Prescription Drug Misuse 
 
The NSDUH contains two separate questions related to workplace absenteeism during the past 
30 days. The first asks respondents how many days they missed work due to sickness or injury; 
the second asks how many days were missed because they did not want to be at work. Our 
outcome variable was total absenteeism, calculated as the sum of the responses to the two 
absenteeism questions. We used the sum because recall bias (i.e., the respondent may have had 
trouble recalling the exact reason for a particular day of absenteeism) and justification or 
desirability bias (i.e., the respondent may be more likely to attribute absenteeism to sickness or 
injury than to a lack of work motivation) may have led to over-reporting of days of missed work 
due to sickness or injury and to under-reporting of days of missed work because someone did not 
want to be at work. As such, we believe that the sum of responses as a measure of total 
absenteeism is likely to suffer less from reporting error than the two separate absenteeism 
responses. 
 
Our primary explanatory variables were three indicators for prescription drug misuse during the 
past 30 days. The NSDUH asks respondents when they last used a particular type of prescription 
drug that was not prescribed to them or that they only took for the experience or feeling that it 
caused. From this we created indicators for past-month misuse of any prescription drug, past-
month misuse of prescription pain relievers and past-month misuse of prescription drugs other 
than pain relievers. 
 
Covariates 
 
We included socioeconomic and demographic covariates in the statistical model, including sex, 
age, education, income, race, marital status, and job type (part-time or full-time). We accounted 
for differences in health status by including a set of indicators for overall health (five categories, 
ranging from excellent health to poor health) and for having experienced serious psychological 
distress during the past month (based on the Kessler-6 scale; Kessler et al., 2003). 
 
Absenteeism may also vary because of differences in workplace characteristics. For example, 
some occupations are associated with more job-related stress, which could lead to higher 
absenteeism rates. Employees at larger organizations may be more absent if they have paid time 
off. To account for such differences, we used indicators for the type of occupation (14 
categories) and organizational size (five categories), and two indicators for the presence of an 
alcohol and drug policy and for drug testing in the workplace. The use of other substances is 
correlated with prescription drug misuse and may affect absenteeism as well. Hence, indicators 
for past-month tobacco use, for heavy alcohol use—based on the standard NSDUH definition of 
having had five or more drinks on a single occasion on 5 or more days during the past 30 days—
and for illegal drug use were included in the model. Because methamphetamine is produced 
legally and illegally, it is addressed in the prescription drug and illicit substances sections of the 
NSDUH (SAMHSA, 2009). To avoid overlap in our indicators, methamphetamine was included 
in the prescription drug misuse indicator when it was reported in the prescription drug section 
but excluded altogether from the indicator for illegal drug use. This was unlikely to affect our 
analysis, as only 0.05% of the unweighted sample reported use of methamphetamines outside of 
the prescription drug module of the survey. 
 
Statistical Analysis 
 
All analyses were conducted with Stata version 13 (Statacorp, 2013). The “svyset” command 
together with survey weights from the NSDUH were used to account for the complex survey 
design. We calculated weighted averages of all variables for the entire sample and separately for 
those who did and those who did not misuse prescription drugs during the prior 30 days. We also 
tested for statistically significant differences between the two groups. 
 
We used a logistic regression model to estimate the relation between prescription drug misuse 
and the probability of being absent from work 1 or more days during the past month, controlling 
for the other covariates. We used a negative binomial regression model to estimate the relation 
between prescription drug misuse and total days of past-month absenteeism, again controlling for 
the other covariates. This model was used because it allows for overdispersion relative to a 
Poisson model (Cameron & Trivedi, 1986, 2005). The logistic model and the negative binomial 
model were estimated twice: once with inclusion of a single indicator for any past-month 
prescription drug misuse, and once with the single misuse indicator replaced by two separate 
indicators for misuse of prescription pain relievers and misuse of other prescription drugs. This 
was done to assess, first, whether an association between prescription drug misuse and 
absenteeism existed, and second, whether the association was different for prescription pain 
relievers compared to other prescription drugs. For each model, we estimated the marginal 
effects (with the “margins” command in Stata) of selected covariates, and the associated standard 
errors, t statistics and p values. For the logistic models, the marginal effect is the (covariate-
adjusted) difference in the probability of being absent between two groups (e.g., those who 
misused prescription drugs and those who did not). For the negative binomial models, the 
marginal effect is the (covariate-adjusted) difference in days of past-month absenteeism between 
two groups. 
 
Results 
 
Table 1 gives sample means for all variables. Between 2008 and 2012 the 30-day prevalence of 
prescription drug misuse among those who reported current employment was 2.7%. Prescription 
pain relievers were more frequently misused (1.9%) than other prescription drugs (1.2%). Those 
in the workforce who misused prescription drugs were more absent from work (1.3 vs. 0.8 days), 
and more likely to be heavy alcohol users, use tobacco, and use illegal drugs. Misusers were 
somewhat less likely to have full-time employment and more likely to work for smaller 
organizations (with fewer than 25 employees). Those who misused prescription drugs were more 
likely to work in certain occupation types, including service, sales, and construction/extraction, 
and less likely to work for employers who have a written drug and alcohol policy, or who 
conduct drug and alcohol testing. They were more likely to be male (56 vs. 53%) and White (76 
vs. 67%), and less likely to be married (34 vs. 57%), compared to those who did not misuse 
prescription drugs. Misusers were also younger, less educated, and had a lower income than 
those who did not misuse. Finally, workers who misused prescription drugs were less likely to 
report excellent overall health (16 vs. 26%) and more likely to have experienced serious 
psychological stress during the past month (13 vs. 3.3%). 
 
 
 
 
 
 
TABLE 1 Characteristics of Prescription Drug Misusers and Nonmisusers in the Workforce; 
2008–2012 National Survey on Drug Use and Health 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Note. The last column contains the values of test statistics and p values, used for testing for 
statistically significant differences in each variable between workers who did and those who did 
not misuse prescription drugs during the past 30 days. For days of absenteeism, we report the 
Wald F-statistic. For all other values, we report a modified F statistic, based on the Pearson chi-
squared test for independence. All statistics were adjusted for the complex survey design. 
 
The distributions of the number of days absent (during the past 30 days) for employees who 
misused prescription drugs and for those who did not misuse are displayed in Figure 1. Those 
who misused prescription drugs were less likely to have no days of absenteeism (64 vs. 77% 
among those who did not misuse), and therefore more likely to have at least 1 day of 
absenteeism. For example, 8.0% of misusers had 2 days of absenteeism, versus 5.6% among 
workers who did not misuse prescription drugs. 
 
Selected estimates from the logistic regression models for the probability of any absenteeism are 
given in Table 2. The variables in Table 1 were used as control variables. We also used a full set 
of pairwise interactions between the indicators for prescription drug misuse, heavy alcohol use, 
and illegal drug use. In Model 1 we used an indicator for any past-month prescription drug 
misuse as primary independent variable. In Model 2, this indicator was replaced by separate 
indicators for past-month misuse of prescription pain relievers and past-month misuse of other 
prescription drugs. From Model 1, we see that misuse of any prescription drug was associated 
with a 7.4%-point increase in the probability of being absent. Illegal drug use and psychological 
distress were associated with increases of 4.3 and 7.4% points, respectively, in the probability of 
any absenteeism. If the workplace had a written drug and alcohol policy, workers were also 
slightly more likely to be absent. Estimates from Model 2 show that misuse of prescription pain 
relievers and misuse of other prescription drugs were associated with 5.5%- and 8.2%-point 
increases in the probability of absenteeism. However, the difference in marginal effects was not 
statistically significant (p = .445). The remaining marginal effects estimated from Model 2 are 
similar to those from Model 1. 
 
 
 
FIGURE 1 Days absent from work (during the past 30 days) among recent prescription drug 
misusers and nonmisusers in the workforce; 2008–2012 National Survey on Drug Use and 
Health. Note. All between-group differences in relative frequencies were statistically significant. 
The smallest value of the F statistic (adjusted for the complex survey design) was 17.0 and all p 
values were less than 0.00. 
 
Table 3 contains estimates from the negative binomial model. The estimated overdispersion 
parameter for Models 3 and 4 was 6.8 in both models (95% confidence interval [CI]: [6.6, 7.0]), 
suggesting that the negative binomial model provided a better fit than a Poisson model. We also 
estimated zero-inflated versions of the negative binomial model (results not reported here). The 
zero-inflated models, however, yielded extreme coefficients and standard errors for some of the 
control variables, which indicated a lack of identification in these specifications. Moreover, we 
were unable to test for zero inflation, because the use of sampling weights renders the 
conventional likelihood-ratio type tests invalid. The standard negative binomial model was 
therefore our preferred specification for days of absenteeism. 
 
 
 
 
Table 2 Logistic Regression Estimates for any Workplace Absenteeism Versus None; 2008–
2012 National Survey on Drug Use and Health 
 
 
Note.All variables listed in Table 1 were used as control variables in the logistic regression 
model, as well as a set of year indicators (2009–2012) and a complete set of pairwise interactions 
between the drug and alcohol use indicators. In Model 1 we used a single indicator for past-
month misuse of any prescription drug. In Model 2, we replaced this by two separate indicators 
for misuse of prescription pain relievers and misuse of prescription drugs, excluding pain 
relievers. 
 
Table 3 Negative Binomial Regression Estimates for Days of Workplace Absenteeism; 2008–
2012 National Survey on Drug Use and Health 
 
 
Note. all variables listed in Table 1 were used as control variables in the negative binomial 
regression model, as well as a set of year indicators (2009–2012) and a complete set of pairwise 
interactions between the drug and alcohol use indicators. In Model 3 we used a single indicator 
for past-month misuse of any prescription drug. In Model 4, we replaced this by two separate 
indicators for misuse of prescription pain relievers and misuse of prescription drugs, excluding 
pain relievers. 
Estimates from Model 3 show that prescription drug misuse was associated with an additional 
0.25 days of past-month absenteeism, or about 3 additional days/year. A similar marginal effect 
(ME) was found for illegal drug use (ME = .19), but the marginal effect for serious psychological 
distress was substantially higher (ME = .68). We tested for heterogeneity of the marginal effect 
of prescription drug misuse across subgroups defined by the heavy alcohol use and illegal drug 
use indicators but found none (p ≥ .394). Finally, drug and alcohol testing in the workplace was 
associated with a statistically significant but small (0.09 days) increase in absenteeism. 
 
Estimates from Model 4 show that misuse of prescription pain relievers was associated with 0.17 
additional days of past-month absenteeism, whereas misuse of other prescription drugs was 
associated with 0.31 additional days of past-month absenteeism, but both marginal effects were 
not statistically significant at the 5% level. The difference between the two marginal effects was 
not statistically significant (p = .528) and the marginal effects did not change significantly 
depending on the use of other substances (results not reported here). Finally, Table 3 shows that 
the marginal effects of illegal drug use, serious psychological distress, and drug and alcohol 
testing in the workplace were very similar to those obtained from Model 3. 
 
Discussion 
 
The Office of National Drug Control Policy's 2013 (ONDCP; 2013) strategic plan recognizes 
workplaces as an important focus for substance abuse prevention efforts. Research drawing a 
link between prescription drug misuse and costs to employers can be a convincing tool for 
creating a business case for employers to invest in workplace prevention efforts. These efforts 
can target not only employees, but also their families, which is particularly important for parents 
of the large number of young people who misuse prescription drugs for the first time every year. 
Research on the specific negative effects of prescription drug misuse on employers and 
workplaces, however, is limited and existing work is based on older data. 
 
The contribution of this article was to analyze the relation between prescription drug misuse and 
absenteeism. Using data from the 2008–2012 NSDUH, we found that misuse of prescription 
drugs was associated with a 7%-point increase in the probability of being absent, and an increase 
of 0.25 days of past-month absenteeism, or about 3 days/year. We did not find evidence to 
suggest that these estimates were different for misuse of prescription pain relievers compared to 
misuse of other prescription drugs. Interestingly, these marginal effects were larger than for 
heavy alcohol use and illegal drug use. Finally, having experienced serious psychological 
distress was also a significant predictor of absenteeism. It was associated with a 7%-point 
increase in the probability of being absent, and an additional 0.68 days of past-month 
absenteeism (about 8 days/year). 
 
A limitation of this study is that we did not estimate the causal effect of prescription drug misuse 
on absenteeism. As such, there are several possible explanations for our empirical findings. First, 
though we found that misusers of prescription drugs are absent more, this could be the causal 
result of some other, unobserved influence. In other words, there may be unobserved 
confounders that lead to increased absenteeism and are positively correlated with prescription 
drug misuse. Second, there could be underlying and unmeasured health, mental health, and 
character-related factors that affect absenteeism and, at the same time, partly determine 
substance use behaviors. Third, absenteeism itself could be a risk factor for prescription drug 
misuse, so that causality might “run both ways.” To estimate causal effects, a different 
estimation approach (e.g., instrumental variables) will be needed, which is a topic for future 
research. A second limitation of this study is that the absenteeism and prescription drug misuse 
responses in the NSDUH may suffer from measurement error due to under-reporting. 
Incorporating the possibility of reporting bias into the statistical model would be an interesting 
future extension of this study. 
 
This study focused on absenteeism and modest associations with prescription drug misuse were 
found. There are of course other workplace outcomes that are of interest. For example, 
prescription drug misuse among workers could lead to higher job turnover, thereby raising costs 
for employers. Analyses of alternative outcomes will necessitate the use of data sources other 
than, or in addition to, the NSDUH. Additional research should also investigate different rates of 
prescription drug misuse based on occupational or industry risk factors. For example, the rate 
among doctors and nurses has been found to be higher than for the general population (Pooler, 
Sheheen, & Davidson, 2009). These findings would allow more prevention efforts to target those 
with the highest risk of misusing prescription drugs. 
 
Conclusion 
 
Prescription drug misuse has become a significant problem in recent years. This study is a step 
toward developing a better understanding of the relation between prescription drug misuse and 
workplace absenteeism. Our results show that prescription drug misuse was associated with an 
increase in the likelihood of absenteeism and a modest increase in days of absenteeism. More 
work is needed to assess causal effects and study other workplace-related variables, including 
presenteeism (diminished on-the-job performance), workplace injuries and job turnover. 
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